ArticleOdontology2025
Investigation of experimental resin composites containing different boron compounds incorporated into mesoporous and nonporous hydroxyapatite nanocarriers.
Article in Odontology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study aimed to investigate the surface hardness, monomer conversion, surface roughness, boron release, and water sorption-solubility properties of experimental resin composites (RC) containing hydroxyapatite nanocarriers (HAP) loaded with different boron compounds, in comparison to a conventional RC. In this study, boron nitride and 4-borono-L-phenylalanine were loaded into mesoporous and nonporous HAP. 1% boron-nanocarrier complexes were added to a conventional resin-composite content. The study groups were designated based on the boron compound and nanocarrier type: Group 1 (Control): (a conventional RC), Group 2: Experimental RC containing mesoporous HAP loaded with boron nitride (BN@MHAP), Group 3: Experimental RC containing nonporous HAP loaded with boron nitride (BN@HAP), Group 4: Experimental RC containing mesoporous HAP loaded with 4-borono-L-phenylalanine (BPA@MHAP), Group 5: Experimental RC containing nonporous HAP loaded with 4-borono-L-phenylalanine (BPA@HAP). Vickers microhardness, surface roughness, degree of monomer conversion, water sorption-solubility, and boron release analyses were conducted on the RC samples. The nanoparticles were characterized using the Energy Dispersive X-ray Spectroscopy (EDX) for elemental analysis and mapping, X-ray Diffraction (XRD) for examining crystal structure, Fourier-Transform Infrared Spectroscopy (FTIR) for evaluating molecular bond structure, and Scanning Electron Microscopy (SEM) for observing surface morphology of mesoporous and non-porous HAP. No statistically significant difference was found between the experimental RC materials containing boron-nanocarrier complexes and the control group in terms of monomer conversion, surface hardness, surface roughness, water sorption and solubility (p > 0.05). However, all experimental groups demonstrated significantly higher boron release rates over time (p < 0.05), with BN@HAP and BPA@MHAP groups exhibiting the highest release rates at all timepoints (p < 0.05). The addition of 1% BN@HAP/MHAP or BPA@HAP/MHAP to the RC is promising for developing an antibacterial RC capable of releasing boron without compromising the tested physico-chemical properties of the material.
Indexed as
Identifiers
39285115What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.